NCT02855697View on ClinicalTrials.gov

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 26, 2017

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib

300 mg taken twice daily, equivalent to a total daily dose of 600 mg

DRUG

Cediranib

20mg dose of cediranib was selected for this study

DRUG

Platinum-based Chemotherapy

1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.

Trial Locations (1)

M20 4BX

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
collaborator

Clinical Trials Unit, Manchester

OTHER

lead

The Christie NHS Foundation Trust

OTHER

NCT02855697 - Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | Biotech Hunter | Biotech Hunter